SCR: Massive Rotator Cuff Tear Reconstruction

Sponsor
Nova Scotia Health Authority (Other)
Overall Status
Recruiting
CT.gov ID
NCT03425500
Collaborator
(none)
60
1
2
62
1

Study Details

Study Description

Brief Summary

To compare bridging reconstruction to superior capsular reconstruction using human dermal allograft augmentation for repair of massive rotator cuff tears.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Bridging Rotator Cuff Reconstruction
  • Procedure: Superior Capsular Reconstruction
  • Device: GRAFTJACKET™ allograft
N/A

Detailed Description

A total of 60 patients will be enrolled in the study. In the pre-operative period, there will be no additional time requirements for the patient, except for the informed consent process for the study. Routine radiographs including an AP and Y view of the shoulder as well as a pre-operative MRI are obtained for all patients undergoing rotator cuff surgery.

The patients will complete a structured clinical examination conducted by a sports medicine fellowship trained orthopaedic consultant. The examination will consist of range of motion testing by goniometer as well as strength testing by hand dynamometer. The patient will also complete the WORC questionnaire.

Surgical Technique

All patients will undergo a 15-point arthroscopic shoulder examination as per the method outlined by Snyder. An arthroscopic acromioplasty will be performed if needed according to the technique described by Snyder. The bursal side of the tear will be evaluated. If the cuff can be re-approximated to its anatomic position on the greater tuberosity without excessive tension, a standard rotator cuff reconstruction will be attempted. If this is not possible the surgeon will determine that the cuff is "irreparable" and the randomization envelope will be opened.

Wong et al. described the surgical procedure for patients in the "Bridging" group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. Following this, an acellular human dermal patch will be rehydrated in saline solution for 15 minutes. The patch is stretched to remove the manufacturing surface irregularities. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed into the remnants of supraspinatus and infraspinatus tendons. The patch is then attached to the greater tuberosity in a double row configuration.

The technique described by Burkhart et al will be followed for patients in the "SCR" group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. Following this, an acellular human dermal patch will be rehydrated in saline solution for 15 minutes. The patch is stretched to remove the manufacturing surface irregularities. Measurement of defect size (coronal and sagittal) will take place, following that the glenoid and humeral footprint preparation will be performed utilizing an arthroscopic burr, arthroscopic bone anchors will be inserted on the glenoid footprint and graft is inserted with double pully technique. The graft is then tensioned to greater tuberosity using a double row configuration.

Postoperative protocol

The shoulder will be immobilized in a sling for one week postoperatively, and only passive forward flexion and external rotation will be allowed for eight weeks. The patient then progresses to active shoulder motion. Strengthening will begin at twelve weeks postoperatively.

The patient will follow-up with the attending surgeon (IW) at 2 weeks post-operatively for a wound check. Then further follow-up appointments will be at 6 weeks, 3 months, 6 months, 12 and 24 months, as per current clinical practice.

At the 3, 6, 12, and 24 month visits the patient will again undergo the structured clinical examination conducted by a sports medicine fellowship trained orthopaedic consultant who is blinded to the patients' treatment group. The patient will also complete the (WORC) questionnaire at these follow-up appointments. Radiograph will be taken also to obtain the postoperative measurements. MRI will be done to assess healing at 12 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized Control TrialRandomized Control Trial
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Bridging Reconstruction of Massive Rotator Cuff Tears by Human Dermal Allograft Augmentation Compared to Superior Capsular Reconstruction
Actual Study Start Date :
May 1, 2018
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bridging Rotator Cuff Group

Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.

Procedure: Bridging Rotator Cuff Reconstruction
Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft

Device: GRAFTJACKET™ allograft
The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
Other Names:
  • Acellular human dermal allograft
  • Active Comparator: Superior Capsular Group

    Superior Capsular Reconstruction of massive rotator cuff tear

    Procedure: Superior Capsular Reconstruction
    Superior Capsular Reconstruction of massive rotator cuff tear

    Outcome Measures

    Primary Outcome Measures

    1. Maintenance of Acromiohumeral Distance [24 months]

      The primary objective of this study is to compare the effect between the two surgical techniques, arthroscopic SCR for a massive, chronic irreparable tear of the rotator cuff vs. BRR with an acellular human dermal allograft implant, on the maintenance of the Acromiohumeral distance. Acromiohumeral Distance is measured in mm and determine through xray.

    Secondary Outcome Measures

    1. Changes in Shoulder Strength After Surgery [24 months]

      Changes in Strength After Surgery will be measured in kilograms using a hand dynamometer.

    2. Changes in Shoulder Range of Motion After Surgery [24 months]

      Changes in Shoulder Range of Motion After Surgery will be measured in degrees using a goniometer.

    3. Changes in Patient Reported Outcomes using the Western Ontario Rotator Cuff Index (WORC) [24 months]

      The Western Ontario Rotator Cuff Index is a questionnaire use to evaluate patient reported outcomes. The questionnaire asks 21 questions are using a 100mm visual analogue type scale patients are asked to indicate how much pain they are experiencing doing different activities. The left end of the line indicates no pain, the right end of the line indicates extreme pain. The distance in mm from the left end of the line determines the amount of pain. To total distances for all 21 questions is added up then subtracted from 2100 and divided by 21 to give a percentage. A percentage of 100 indicates that no pain is being felt and low percentages indicates the patient is experiencing extreme pain.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Magnetic resonance imaging (MRI) proven diagnosis of a large or massive (>3cm), two-tendon (supraspinatus and infraspinatus) tear of the shoulder rotator cuff
    Exclusion Criteria:
    • Presence of subscapular tear

    • Presence of glenohumeral osteoarthritis

    • WORC score > 70%

    • Uncontrolled diabetes

    • Pregnancy

    • Presence of local or systemic infection

    • Paralysis of the shoulder

    • Poor nutritional state

    • Contracture of the shoulder

    • Presence of cuff tear arthropathy

    • MRI proven nonvascular surgical sites

    • Cancer

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Nova Scotia Health Authority Halifax Nova Scotia Canada B3H 2E1

    Sponsors and Collaborators

    • Nova Scotia Health Authority

    Investigators

    • Principal Investigator: Ivan H Wong, MD, Nova Scotia Health Authority

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ivan Wong, Orthopaedic Surgeon MD FRCS(C), Dip. Sports Medicine, Nova Scotia Health Authority
    ClinicalTrials.gov Identifier:
    NCT03425500
    Other Study ID Numbers:
    • IW-002
    First Posted:
    Feb 7, 2018
    Last Update Posted:
    Mar 8, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 8, 2022